The Clinical TMS Society (CTMSS) held its 2026 Annual Meeting in Boston from June 4 to 6, drawing an international field of TMS providers and researchers. The program included the PULSES and Pain Academy pre-conference training courses, followed by two days of keynotes, poster sessions, and device demonstrations.
The meeting was the launchpad for several major device-maker announcements. Neuronetics presented real-world TrakStar data on TMS effectiveness by age and sex, adolescent outcomes, and a plenary on maintenance therapy. BrainsWay presented its first 12-month durability data for the SWIFT accelerated Deep TMS protocol. MagVenture exhibited fresh off its late-May FDA clearance for accelerated TMS protocols.
The dominant themes — accelerated protocols, maintenance therapy, neuronavigation, and adolescent treatment — map closely to where the field is heading commercially in the second half of 2026.
For clinic operators, the meeting offered a preview of the protocols and technologies most likely to shape patient demand and payer conversations over the coming year.
Source
Reporting based on coverage from Clinical TMS Society. This article is editorial summary intended for general information; it is not medical advice.
